A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.


Updates from The Motley Fool

Latest updates on MannKind from Fool.com.  The Fool has written over 400 articles on MannKind.
4 Stocks I'd Avoid at All Costs

Developing and commercializing new drugs involves so many uncertainties that even the finest biot...

3 Stocks to Avoid in Biotech

Image source: Getty Images. Public outrage over escalating drug prices made the biotechnology ind...



Stock Performance

View Interactive MNKD Charts
Sponsored by

Key Data Points

Primary metrics and data points about MannKind.
Current Price: $0.62
Prev Close: $0.64
Open: $0.65
Bid: $0.62
Ask: $0.66
Day's Range: $0.61 - $0.67
52wk Range: $0.41 - $2.24
Volume: 4,508,166
Avg Vol 4,293,709
Market Cap: $254M
P/E (ttm): -1.24
EPS (ttm): ($0.52)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about MannKind.
CAPS Rating 1 out of 5
 
696 Outperform
136 Underperform
CAPS All Stars
 
77 Outperform
36 Underperform

How do you think MannKind will perform against the market?



You pick for MannKind is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Matthew J. Pfeffer, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for MannKind.

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers